Clinical Trials Logo

Esophageal Carcinoma clinical trials

View clinical trials related to Esophageal Carcinoma.

Filter by:

NCT ID: NCT05795595 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Start date: March 13, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.

NCT ID: NCT05780736 Recruiting - Clinical trials for Esophageal Carcinoma

A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer

PROSPECT-ESO
Start date: August 4, 2023
Phase:
Study type: Observational

The purpose of this study is to describe the effectiveness and use of nivolumab after surgery in participants with early stage (Stage II/III) Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC).

NCT ID: NCT05777707 Recruiting - Clinical trials for Esophageal Carcinoma

Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma

Start date: October 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This prospective study aims to clarify the clinical efficacy and survival prognosis of neoadjuvant immune checkpoint inhibitor (ICI) combined with chemotherapy for esophageal cancer. It also explores predictive biomarkers and potential therapeutic targets for locally advanced esophageal cancer based on plasma metabolomics and peripheral blood immune cell clustering analysis. Each patient received 2-3 cycles of neoadjuvant immunotherapy with programmed cell death 1 (PD-1) blockade in combination with albumin paclitaxel and platinum. Exploratory analysis of plasma metabolomics combined with peripheral blood subsets of immune cells can reveal biomarkers that predict the efficacy and prognosis of patients undergoing neoadjuvant immunotherapy for locally advanced esophageal cancer, which also provide new ideas for the selection of immune adjuvants and therapeutic targets in ICIs combination therapy strategies.

NCT ID: NCT05775939 Recruiting - Lung Carcinoma Clinical Trials

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

Start date: January 20, 2023
Phase: N/A
Study type: Interventional

This clinical trial examines positron emission tomography (PET)/computed tomography (CT) in evaluating cardiac radiation damage in patients with lung or esophageal cancer. As part of the treatment for lung or esophageal cancer, patients will undergo radiation therapy. Sometimes, during this treatment, the heart is also subjected to some radiation which could affect its function, either increasing or decreasing the function. It is not known the consequences of this change nor is it known if doctors can detect the changes associated with the radiation. Sarcoidosis FDG positron emission tomography (PET)-computed tomography (CT) scans are a common way to image cardiac inflammation and myocardial viability. This study may help doctors image the heart before, during and after radiotherapy to monitor any changes.

NCT ID: NCT05476380 Recruiting - Clinical trials for Esophageal Carcinoma

Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Start date: February 19, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of neoadjuvant therapy of camrelizumab combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma

NCT ID: NCT05059444 Recruiting - Clinical trials for Non-small Cell Lung Cancer

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

ORACLE
Start date: September 7, 2021
Phase:
Study type: Observational

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

NCT ID: NCT04652180 Recruiting - Esophageal Cancer Clinical Trials

Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy .

CIR·ROB
Start date: November 6, 2020
Phase: N/A
Study type: Interventional

This is a randomized controlled trial designed to compare robot-assisted thoracic approach with open transthoracic esophagectomy (Ivor Lewis technique) as a surgical treatment for resectable esophageal cancer. If our hypothesis is proved correct, robot-assisted thoracic approach will result in a lower percentage of respiratory and overall postoperative complications, lower blood loss, shorter hospital stay, but with at least similar oncologic outcomes and better postoperative quality of life compared with the open transthoracic esophagectomy (current standard).

NCT ID: NCT04607590 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Yoga Program for Improving the Quality of Life in Couples Coping With Cancer

Start date: May 31, 2019
Phase:
Study type: Observational

This clinical trial seeks to learn if a yoga program can improve physical performance, quality of life and symptom burden in cancer patients who are undergoing radiation therapy, and their partners. Taking part in yoga or stretching sessions may lower distress, improve quality of life, and/or may improve sleep and fatigue for cancer patients and their caregivers.

NCT ID: NCT04517019 Recruiting - Clinical trials for Head and Neck Cancer

Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy

OnkoFit II
Start date: August 1, 2020
Phase: N/A
Study type: Interventional

Evaluation of the impact of an activity tracker based fitness programme on the Qualitiy of Life after oncological therapy.

NCT ID: NCT04505553 Active, not recruiting - Clinical trials for Pancreatic Carcinoma

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial investigates how well oral cryotherapy plus acupressure and acupuncture compared with oral cryotherapy alone work in decreasing chemotherapy-induced peripheral neuropathy in patients with gastrointestinal cancer who are receiving oxaliplatin-based chemotherapy. Acupressure is the application of pressure or localized massage to specific sites on the body to control symptoms such as pain or nausea. Acupuncture is the technique of inserting thin needles through the skin at specific points on the body to control pain and other symptoms. Cryotherapy uses cold temperature such as oral ice chips to prevent abnormally increased pain sensation. Giving oral cryotherapy with acupressure and acupuncture may work better in decreasing chemotherapy-induced peripheral neuropathy from oxaliplatin-based chemotherapy in patients with gastrointestinal cancer compared to oral cryotherapy alone.